Navigation Links
Antibody key to treating variant CJD, scientists find

Scientists at the University of Liverpool have determined the atomic structure of the 'binding' between a brain protein and an antibody that could be key to treating patients with diseases such as variant CJD.

Variant Creutzfeldt-Jakob Disease (vCJD) is part of a family of rare progressive neurodegenerative disorders, called prion diseases, which affect both animals and humans. It is thought that those who have developed vCJD became infected through the consumption of cattle products contaminated with Bovine Spongiform Encephalopathy (BSE) a brain disorder in cows, commonly known as Mad Cow Disease.

Prion diseases can develop when a naturally occurring brain prion protein called, PrP, comes into contact with infectious prions. This converts PrP into a form that has a different shape, and eventually leads to a build-up of protein in the brain, causing brain cells to die. It is thought that immunisation with antibodies that can 'stick' to PrP could treat and even prevent the development of the disease.

To understand the 'connection' between the antibody and the protein, scientists at Liverpool used X-ray crystallography technology to build a three-dimensional picture of the binding between an antibody called ICSM18 designed to 'stick' effectively to prion proteins and PrP cells.

Samar Hasnain, Professor of Molecular Biophysics at the University, explains: "To pin-point where the antibody 'sticks' to the protein we used X-ray crystallography, pioneered by Nobel Prize winner Max Perutz. Significantly we found that the point at which the protein and antibody came together was also where scientists at the Medical Research Council (MRC) Prion Unit had identified a single amino acid, which we now know has a significant impact on a patient's susceptibility to prion disease."

Scientists at the MRC Prion Unit, University College London, who collaborated on the research, have found that ICSM18 could help prevent brain cells from becoming infected as well as reverse early damage caused by the disease.

Professor John Collinge, Director of the MRC Prion Unit, added: "We have shown that ICSM18 has the highest therapeutic potential in animal and cell based studies, but we have yet to establish its impact on people who have vCJD or other prion diseases. We are currently working, however, to make human versions of the antibodies for future trials in people."


Contact: Samantha Martin
University of Liverpool

Related biology news :

1. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
2. ETH Zurich researchers develop antibody test
3. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
4. Yale chemist receives NIH Young Investigator Award for antibody targeting
5. Reversing cognitive deficits: Injectable antibody may attack source of problem
6. Studies point to novel target for treating arrhythmias
7. World breakthrough in treating premature babies
8. UC Davis discovery offers hope for treating kidney cancer
9. Pitt research identifies new target in brain for treating schizophrenia
10. Commercial aquatic plants offer cost-effective method for treating wastewater
11. New approach to treating cystic fibrosis lung infection shows promise
Post Your Comments:
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that the ... of Modern, will feature the Wocket® smart wallet for ... . Touch Of Modern is an ... products to its 7.2 million members. Customers are affluent, ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... Keck Medicine of the University of Southern California (USC) Pain Center ... to Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
(Date:10/12/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... developing and commercializing novel treatments in oncology, endocrinology and ... Turpin , the Company,s former Senior Vice President, Chief ... Quebec City office.  ... Officer of the Company commented, "After a comprehensive review, ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, ... joined the firm as a Premier Expert consultant. NDA Partners Premier Experts ... extraordinary value to the company's clients. Premier Experts collaborate to design and ...
Breaking Biology Technology: